Incidence of prostate cancer will double by the year 2030: the argument against.

Abstract

No one doubts that the incidence of histologically diagnosed prostate cancer will increase markedly in the future; the increasing ageing population, greater awareness, and meticulous pathological search will all confirm and exaggerate known trends. The crucial question of whether the incidence of biologically significant prostate cancer diagnosed in asymptomatic younger men (< 65 years) will double by 2030 and whether urologists are comfortable with the concept of radical therapy for each and every one of these anxious patients remains debatable and unanswered at this time.